Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy in “deep B-cell depletion” for autoimmune disease, emphasizing rheumatoid arthritis (RA) as its lead indication and positioning its natural killer (NK) cell-based approach as potentially more compatible with community administration than T-cell-based modalities.
Deep B-cell depletion focus and indication strategy
President and CEO Dr. Fred Aslan said deep B-cell depletion “promises to be one of the most transformational mechanisms” in autoimmune disease, pointing to the breadth of activity seen with autologous CAR-T across multiple diseases. He argued the key competitive question is not whether the mechanism works, but how a company chooses indications and a target product profile that can be first and meaningfully differentiated.
Why rheumatoid arthritis is the lead program
Aslan framed RA as the largest autoimmune indication and described a major unmet need in later-line patients. He cited typical ACR50 response rates at six months as patients move through successive targeted therapies:
- Mid-30% to mid-40% ACR50 for patients receiving their first targeted agent (TNF or JAK)
- Approximately 20% to 35% after inadequate response to a first targeted mechanism and switching to a second
- Approximately 10% to 20% after inadequate response to two distinct targeted mechanisms, when patients often cycle through third, fourth, and fifth options
Artiva’s stated goal is to treat patients after failure of two targeted therapies and drive ACR50 at six months to around 50% in that population. Aslan said the company believes it can be the first deep B-cell depleting therapy to enter the RA market in this setting, and he noted that roughly 25% of patients who receive targeted therapies become refractory to two distinct classes. He also said that out of roughly $20 billion in RA sales today, around $5 billion is associated with patients receiving a “third drug” despite a low probability of response.
Looking ahead, Aslan said the company expects to interact with the FDA in the first half of 2026 to discuss what a pivotal trial could look like in RA.
AlloNK approach, scalability, and manufacturing claims
Artiva emphasized that its NK cell platform is not genetically engineered; instead, it uses a monoclonal antibody to target B cells. The antibody binds to the B-cell antigen and the Fc portion activates the NK cells, which then attack the pathogenic B cells.
Aslan also highlighted manufacturing and supply chain attributes. The company sources NK cells from umbilical cord units and selects units with a KIR-B haplotype and high-affinity CD16, aiming to improve binding to monoclonal antibodies without genetic engineering. From a single cord unit, the company said it can generate “thousands of vials” that can be cryopreserved for three to four years, vialed in infusion-ready media, thawed at the bedside, and administered as a 5–10 minute IV infusion.
Aslan said Artiva operates a 9,000 square foot facility in San Diego that, at capacity, could treat about 1,000 patients. He also discussed cost of goods expectations, stating the company anticipates a COGS of $1,000 or less per vial containing 1 billion cells, with a low dose of 3 billion cells and a high dose of 12 billion cells in its “one-and-done” regimen.
Autoimmune safety and community administration experience
Aslan pointed to data presented in November from the first 32 autoimmune patients treated, emphasizing an absence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). He said there was no tocilizumab use and that infection rates were in line with rituximab alone. He also said the company has not observed hypogammaglobulinemia and has not required IVIG use to address it.
On feasibility in the community setting, Aslan described a hospitalization summary over the first 28 days of treatment. He said that among the first 32 patients, only one hospitalization occurred, related to an ear infection treated with IV antibiotics. He added that most patients were treated by community rheumatologists, with cyclophosphamide and fludarabine (Cy/Flu) administered in infusion chairs followed by discharge home.
Addressing skepticism about Cy/Flu outside academic centers, Aslan argued that these agents have been used in tens of thousands of patients in the autologous CAR-T setting, typically as outpatient conditioning, with hospitalizations driven more by CAR-T-related side effects. He characterized the main expected impact at the doses used as pancytopenia lasting about two to three weeks, managed with monitoring and infection precautions. He also noted fertility concerns as a challenge, which influenced Artiva’s preference for RA and other indications with older patient populations compared with lupus.
Evidence of deep B-cell depletion and upcoming RA data
Aslan said Artiva developed a high-sensitivity B-cell assay with a lower limit of detection of 0.1 cells per microliter to better quantify residual B cells. He contrasted this with typical assays and referenced a rituximab dataset in which B cells remained detectable in 40% of patients using a high-sensitivity approach. In Artiva’s samples available at the time of the November disclosure, he said all patients had no detectable B cells using the company’s assay.
For near-term clinical updates, management reiterated guidance that it expects to share data in the first half of 2026 on at least 15 RA patients, with most having six months or more of follow-up. Aslan said the company aims to show sufficient evidence that the therapy has the potential to achieve ACR50 of 50% or greater at six months, acknowledging that earlier RA work began as an investigator-initiated trial before transitioning to a company-sponsored study and may not include every ACR50 component in all patients.
On pivotal trial design, Aslan said Artiva prefers a randomized controlled trial, in part to address questions around the contribution of rituximab versus the full regimen. He suggested a design that randomizes patients to rituximab versus Artiva’s therapy could be feasible with “relatively small numbers” if the effect size is as large as the company is targeting, while noting the final patient numbers and safety database requirements will depend on FDA feedback.
Beyond RA, Aslan said the company remains interested in Sjögren’s, scleroderma, and myositis, with particular interest in Sjögren’s due to its size and the importance of community access, while noting there has been less validation of Sjögren’s with B-cell depletion than in some other diseases. He said Artiva plans a data-driven approach “one indication at a time.”
Aslan concluded that investors should focus less on identifying a single winner in deep B-cell depletion and more on which companies can be first in specific indications with a product profile that is meaningfully better than standard of care. He also noted Artiva reported $123 million in cash as of the end of the third quarter of the prior year, which he said provides runway into the second quarter of 2027.
About Artiva Biotherapeutics (NASDAQ:ARTV)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Artiva Biotherapeutics
- CSE: ALEN.U is targeting a fast-growing digital wellness market
- New Copper-Rich “Kraken” Zone Discovered
- 1,500 Banks Just Handed the Fed Your Bank Account
- Silver paying 20% dividend. Plus 68% share gains
- 3 Signs You May Want to Switch Financial Advisors
